A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung Cancer

Phase 1

Conditions: Stage IV non-small cell lung cancer
MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864
Therapeutic area: Diseases [C] - Neoplasms [C04]

Registration Number: CTIS2022-500990-16-00

Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 266

Inclusion Criteria

Has a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced disease, Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly accelerated fibrosarcoma- (B-Raf-) directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR mutations, B-Raf mutations, ALK gene rearrangements, and ROS1 gene rearrangements), Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology, Male participants must agree to use contraception during the treatment period and for =120 days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condom, Female participants eligible to participate if not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow contraceptive guidance during the treatment period and for =120 days after the last dose of study treatment, Provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated, Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, Has adequate organ function

Exclusion Criteria

Has significant cardiovascular impairment within 12 months of the first dose of study drug: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA) stroke, or cardiac arrhythmia associated with hemodynamic instability, significant cardiovascular impairment, or a left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram, Has received prior systemic chemotherapy treatment for metastatic/recurrent NSCLC, Has current NSCLC disease that can be treated with curative intent with surgical resection, localized radiotherapy, or chemoradiation, Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical resection), Has received prior therapy with an anti–PD-1, anti–PD-L1, or anti–PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor, Has received previous treatment with another agent targeting the Lymphocyte-activation gene 3 (LAG-3) receptor, Has received previous treatment with another agent targeting vascular endothelial growth factor (VEGF) or the VEGF receptor, Has received prior anticancer therapy including investigational agents within 4 weeks prior to randomization, Has received prior radiotherapy within 2 weeks of start of study treatment or received lung radiation therapy of >30 Gy within 6 months prior to the first dose of study intervention, Has received a live or live-attenuated vaccine within 30 days before the first dose of study treatment, Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment, Prolongation of QTc interval to >480 milliseconds (ms), Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment, Has a known additional malignancy that is progressing or has required active treatment within the past 3 years, Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis, Has severe hypersensitivity (=Grade 3) to pembrolizumab, favezelimab, or lenvatinib and/or any of its excipients, Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs), Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis, Has an active infection requiring systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection, Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection, Has a known history of active tuberculosis (TB; Bacillus tuberculosis), Has symptomatic ascites or pleural effusion, Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the p

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To evaluate the clinical activity (as assessed by objective response rate [ORR]) of specific pembrolizumab-based combinations.;Secondary Objective: To evaluate the clinical activity (as assessed by progression-free survival [PFS] and overall survival [OS]) of specific pembrolizumab-based combinations. PFS and OS to different specific pembrolizumab-based combinations will be assessed independently in each biomarker defined group, To determine the safety and tolerability of pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. Safety and tolerability to different specific pembrolizumab-based combinations will be assessed independently in each biomarker-defined group.;Primary end point(s): Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s):Progression Free Survival (PFS) per RECIST 1.1;Secondary end point(s):Overall Survival (OS);Secondary end point(s):Number of Participants Experiencing Adverse Events (AEs);Secondary end point(s):Number of Participants Discontinuing Study Drug Due to AEs

Related Trials